Baxter International Future Growth
Future criteria checks 3/6
Baxter International is forecast to grow earnings and revenue by 35.1% and 3.6% per annum respectively. EPS is expected to grow by 33.6% per annum. Return on equity is forecast to be 16.8% in 3 years.
Key information
35.1%
Earnings growth rate
33.6%
EPS growth rate
| Medical Equipment earnings growth | 16.5% |
| Revenue growth rate | 3.6% |
| Future return on equity | 16.8% |
| Analyst coverage | Good |
| Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14
Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 05Baxter International Inc.'s (NYSE:BAX) Intrinsic Value Is Potentially 26% Above Its Share Price
Apr 24Is Baxter International (NYSE:BAX) Using Too Much Debt?
Apr 03Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 18Investors Could Be Concerned With Baxter International's (NYSE:BAX) Returns On Capital
Feb 10Baxter International: Another YoY Earnings Decline Expected, Shares Tag Support
Feb 03Why Baxter Is One Of My #1 2023 Bets For Healthcare/Medtech
Jan 02An Intrinsic Calculation For Baxter International Inc. (NYSE:BAX) Suggests It's 32% Undervalued
Dec 30Baxter cut to hold at Deutsche Bank on inflation pressures
Dec 15Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Nov 18Baxter International: Despite Weakening On The Bottom Line, Shares Look Attractive
Oct 24Here's What's Concerning About Baxter International's (NYSE:BAX) Returns On Capital
Oct 05Baxter is said to evaluate sale of two of its kidney businesses
Sep 14Baxter reaches 52-week low; stock down 34% YTD
Aug 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 16,342 | 1,190 | N/A | 2,066 | 7 |
| 12/31/2025 | 15,682 | 960 | 1,373 | 2,008 | 14 |
| 12/31/2024 | 15,107 | 747 | 1,986 | 950 | 14 |
| 12/31/2023 | 14,813 | -76 | 1,034 | 1,726 | N/A |
| 9/30/2023 | 15,280 | 225 | 891 | 1,634 | N/A |
| 6/30/2023 | 15,181 | -2,817 | 829 | 1,559 | N/A |
| 3/31/2023 | 15,068 | -2,440 | 771 | 1,482 | N/A |
| 12/31/2022 | 14,506 | -2,666 | 591 | 1,211 | N/A |
| 9/30/2022 | 14,275 | -2,568 | 792 | 1,465 | N/A |
| 6/30/2022 | 13,892 | 876 | 1,159 | 1,850 | N/A |
| 3/31/2022 | 13,396 | 992 | 1,341 | 2,053 | N/A |
| 12/31/2021 | 12,146 | 1,022 | 1,531 | 2,222 | N/A |
| 9/30/2021 | 12,451 | 1,214 | 1,496 | 2,241 | N/A |
| 6/30/2021 | 12,197 | 1,120 | 1,354 | 2,076 | N/A |
| 3/31/2021 | 11,817 | 1,068 | 1,265 | 1,973 | N/A |
| 12/31/2020 | 11,673 | 1,102 | 1,159 | 1,868 | N/A |
| 9/30/2020 | 11,531 | 911 | 1,236 | 1,985 | N/A |
| 6/30/2020 | 11,410 | 924 | 1,416 | 2,176 | N/A |
| 3/31/2020 | 11,526 | 991 | 1,487 | 2,248 | N/A |
| 12/31/2019 | 11,362 | 1,001 | 1,408 | 2,104 | N/A |
| 9/30/2019 | 11,156 | 1,335 | 1,201 | 1,984 | N/A |
| 6/30/2019 | 11,066 | 1,484 | 981 | 1,739 | N/A |
| 3/31/2019 | 11,060 | 1,505 | 929 | 1,698 | N/A |
| 12/31/2018 | 11,099 | 1,552 | 1,286 | 2,017 | N/A |
| 9/30/2018 | 11,063 | 1,065 | 1,020 | 1,699 | N/A |
| 6/30/2018 | 11,009 | 795 | 1,180 | 1,848 | N/A |
| 3/31/2018 | 10,763 | 840 | 1,409 | 2,095 | N/A |
| 12/31/2017 | 10,584 | 609 | 1,078 | 1,714 | N/A |
| 9/30/2017 | 10,432 | 1,025 | N/A | 2,036 | N/A |
| 6/30/2017 | 10,283 | 904 | N/A | 1,963 | N/A |
| 3/31/2017 | 10,263 | 1,852 | N/A | 2,176 | N/A |
| 12/31/2016 | 10,163 | 4,966 | N/A | 1,654 | N/A |
| 9/30/2016 | 10,121 | 4,909 | N/A | 1,665 | N/A |
| 6/30/2016 | 10,050 | 4,784 | N/A | 1,388 | N/A |
| 3/31/2016 | 9,940 | 3,646 | N/A | 1,342 | N/A |
| 12/31/2015 | 9,968 | 393 | N/A | 1,771 | N/A |
| 9/30/2015 | 10,154 | 337 | N/A | 2,190 | N/A |
| 6/30/2015 | 10,376 | 510 | N/A | 2,849 | N/A |
| 3/31/2015 | 9,274 | 84 | N/A | 2,752 | N/A |
| 12/31/2014 | 10,719 | 457 | N/A | 3,215 | N/A |
| 9/30/2014 | 12,252 | 739 | N/A | 3,155 | N/A |
| 6/30/2014 | 13,253 | 1,092 | N/A | 3,207 | N/A |
| 3/31/2014 | 15,367 | 1,967 | N/A | 3,371 | N/A |
| 12/31/2013 | 9,413 | 315 | N/A | 3,198 | N/A |
| 9/30/2013 | 14,398 | 2,097 | N/A | 3,060 | N/A |
| 6/30/2013 | 14,165 | 2,152 | N/A | 2,841 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: BAX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BAX is expected to become profitable in the next 3 years.
Revenue vs Market: BAX's revenue (3.6% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: BAX's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAX's Return on Equity is forecast to be low in 3 years time (16.8%).